Piper Sandler: Maintains its neutral rating on Pacific Biosciences (PACB.US), adjusting from neutral to neutral rating, with a target price adjusted from $6.50 to $2.00.
Piper Sandler：维持Pacific Biosciences(PACB.US)评级，由中性调整至中性评级, 目标价由6.50美元调整至2.00美元。
Piper Sandler: Maintains Pacific Biosciences (PACB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $6.50 to $2.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.